Business
Zhongchao Inc. Builds A Patient DOT Management System
SHANGHAI, China, Aug. 12, 2021 /PRNewswire/ -- Zhongchao Inc. (NASDAQ: ZCMD) ("Zhongchao" or the "Company"), a healthcare services company offering patient
About this update from Zhongchao Inc.
[{"type":"text","content":" SHANGHAI, China, Aug. 12, 2021 /PRNewswire/ -- Zhongchao Inc. (NASDAQ: ZCMD) (\"Zhongchao\" or the \"Company\"), a healthcare services company offering patient management, online healthcare information, professional training and educational services, today announced that its subsidiary Shanghai Zhongxin Medical Technology Co., Ltd. (\"Zhongxin\") launches Treatment Outcome Oriented DOT Management System (\"DOT Management System\") to accelerate the development of patient management business, meeting the increasing demand in tumor and rare disease patient management market.\nIn the early stage of treatment for tumor and rare disease, many patients discontinue medications due to lack of confidence in the efficacy of the medications or adverse reactions to the medication. The DOT Management System launched by Zhongxin is designed to address this situation. DOT stands for duration of therapy. Antineoplastic drugs need certain treatment time to take effect, and as a result, the length of DOT affects the progression and risks of disease. The DOT Management System aims at improving patient treatment outcomes, by evaluating curative effects through medical models and predicting and warning patients of possible adverse reactions. Meanwhile, the DOT Management System will establish a refined plan based on each patient's condition and carry out effective interventions such as providing corresponding education and guidance for each patient to let them learn in advance any possible adverse reactions or any feasible measures to relieve such adverse reactions during their medications, in order to ease patients' concerns or fears of adverse reactions, guarantee their duration of therapy and improve their adherence to treatment for the goal of treatment outcome improvements. \nDOT is the key to deliver maximum benefits to patients as it allows for the maximum efficacy of drugs. DOT also directly affects the clinical application and market sales of drugs, becoming a new engine for the development of the oncology drug market. In recent years, more and more pharmaceutical companies realize that DOT management is a key factor affecting the ultimate market performance of their drugs. Zhongchao is able to seize the ever-growing market opportunities for organic growth with its extensive pharmaceutical company client resources, in-depth service experie...